These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 12788872)

  • 1. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.
    Steidle C; Schwartz S; Jacoby K; Sebree T; Smith T; Bachand R;
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2673-81. PubMed ID: 12788872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
    McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA
    BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.
    Seidman SN; Klein DF
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6358-9. PubMed ID: 15579803
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning.
    Seftel AD; Mack RJ; Secrest AR; Smith TM
    J Androl; 2004; 25(6):963-72. PubMed ID: 15477371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.
    Simon J; Braunstein G; Nachtigall L; Utian W; Katz M; Miller S; Waldbaum A; Bouchard C; Derzko C; Buch A; Rodenberg C; Lucas J; Davis S
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5226-33. PubMed ID: 16014407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.
    Miller KK; Biller BM; Beauregard C; Lipman JG; Jones J; Schoenfeld D; Sherman JC; Swearingen B; Loeffler J; Klibanski A
    J Clin Endocrinol Metab; 2006 May; 91(5):1683-90. PubMed ID: 16478814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
    Rogol AD; Tkachenko N; Bryson N
    Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men.
    Brill KT; Weltman AL; Gentili A; Patrie JT; Fryburg DA; Hanks JB; Urban RJ; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5649-57. PubMed ID: 12466367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
    Braunstein GD; Sundwall DA; Katz M; Shifren JL; Buster JE; Simon JA; Bachman G; Aguirre OA; Lucas JD; Rodenberg C; Buch A; Watts NB
    Arch Intern Med; 2005 Jul; 165(14):1582-9. PubMed ID: 16043675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.
    Shifren JL; Davis SR; Moreau M; Waldbaum A; Bouchard C; DeRogatis L; Derzko C; Bearnson P; Kakos N; O'Neill S; Levine S; Wekselman K; Buch A; Rodenberg C; Kroll R
    Menopause; 2006; 13(5):770-9. PubMed ID: 16932240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels.
    Bhasin S; Storer TW; Asbel-Sethi N; Kilbourne A; Hays R; Sinha-Hikim I; Shen R; Arver S; Beall G
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3155-62. PubMed ID: 9745419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.
    Page ST; Amory JK; Bowman FD; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1502-10. PubMed ID: 15572415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up.
    Behre HM; Tammela TL; Arver S; Tolrá JR; Bonifacio V; Lamche M; Kelly J; Hiemeyer F; ; Giltay EJ; Gooren LJ
    Aging Male; 2012 Dec; 15(4):198-207. PubMed ID: 22834649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.